Baird Reiterates Outperform Rating on Editas Medicine (EDIT) following earnings

Baird analyst Jack K. Allen reiterated an Outperform rating and $6.00 price target on Editas Medicine (NASDAQ: EDIT)

The analyst commented, "Editas announced 4Q25/FY25 earnings/pipeline updates, highlighted by the continued advancement of EDIT-401, their in vivo program targeting LDL-R upregulation, towards the clinic. Heterozygous familial hypercholesterolemia (HeFH) was announced as the initial target indication of interest for EDIT-401, which makes sense given the high unmet need in this space. Looking ahead, we anticipate that additional preclinical safety/efficacy data from EDIT-401 should set the stage for a mid-26 IND/CTA submission, with initial clinical proof-of-concept data still expected by YE26."

For an analyst ratings summary and ratings history on Editas Medicine click here. For more ratings news on Editas Medicine click here.

Shares of Editas Medicine closed at $2.00 yesterday.

You May Also Be Interested In

• HSBC Downgrades China Power International (2380:HK) (CPWIF) to Hold
• Goldman Sachs Downgrades AAC Technologies Holdings Inc. (2018:HK) (AACAY) to Neutral
• Bernstein SocGen on Meta Platforms Inc. (META): 'Risk-reward remains attractive'